"Oncogene Proteins, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities.
| Descriptor ID |
D009856
|
| MeSH Number(s) |
D12.776.624.664.520 D12.776.964.700
|
| Concept/Terms |
Oncogene Proteins, Viral- Oncogene Proteins, Viral
- Viral Oncogene Proteins
- Viral Transforming Proteins
- Transforming Proteins, Viral
- v-onc Proteins
- v onc Proteins
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Viral".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Viral".
This graph shows the total number of publications written about "Oncogene Proteins, Viral" by people in this website by year, and whether "Oncogene Proteins, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Proteins, Viral" by people in Profiles.
-
A TGF-?1 genetic variant at the miRNA187 binding site significantly modifies risk of HPV16-associated oropharyngeal cancer. Int J Cancer. 2018 09 15; 143(6):1327-1334.
-
Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. Mol Carcinog. 2014 Aug; 53(8):648-58.
-
Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int J Cancer. 2011 Sep 15; 129(6):1362-72.
-
Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res. 2010 Sep 15; 70(18):7199-208.
-
Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA). World J Surg. 2009 Apr; 33(4):653-60.
-
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell. 2008 Dec 05; 32(5):718-26.
-
Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro. Bioorg Med Chem. 2008 May 15; 16(10):5815-25.
-
Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem. 2008 Feb 01; 283(5):2793-803.
-
Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine. 2007 Apr 30; 25(17):3302-10.
-
The role of human papillomavirus in squamous carcinoma of the head and neck. Curr Oncol Rep. 2006 Mar; 8(2):130-9.